Hip fracture incidence is decreasing in the high incidence area of Oslo, Norway

Osteoporosis International

Volumn 23, Issue 10, 2012, Pages 2527-2534

  Stoen R O ^a   Nordsletten, L ^a,c   Meyer, H E ^c,d   Frihagen, J F ^a   Falch, J A ^d   Lofthus, C M ^b,c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Bisphosphonates; Epidemiology; Hip fracture; Incidence; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; DRUG EFFECT; DRUG USE; FEMALE; HIP FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NORWAY; OSTEOPOROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG UTILIZATION; EMIGRATION AND IMMIGRATION; FEMALE; HIP FRACTURES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NORWAY; SEX DISTRIBUTION;

EID: 84867331417     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1888-3     Document Type: Article

References (39)

1. Osnes EK, Lofthus CM, Meyer HE, Falch JA, Nordsletten L, Cappelen I, Kristiansen IS (2004) Consequences of hip fracture on activities of daily life and residential needs. Osteoporos Int 15:567-574
2. Lu-Yao GL, Keller RB, Littenberg B, Wennberg JE (1994) Outcomes after displaced fractures of the femoral neck. A metaanalysis of one hundred and six published reports. J Bone Joint Surg Am 76:15-25
3. Shi N, Foley K, Lenhart G, Badamgarav E (2009) Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. Bone 45:1084-1090
4. Lofthus CM, Osnes EK, Falch JA, Kaastad TS, Kristiansen IS, Nordsletten L, Stensvold I, Meyer HE (2001) Epidemiology of hip fractures in Oslo, Norway. Bone 29:413-418
5. Leslie WD, O'Donnell S, Jean S, Lagace C, Walsh P, Bancej C, Morin S, Hanley DA, Papaioannou A, for the Osteoporosis Surveillance Expert Working Group (2009) Trends in hip fracture rates in Canada. JAMA 302:883-889
6. Ahlborg HG, Rosengren BE, Jarvinen TL, Rogmark C, Nilsson JA, Sernbo I, Karlsson MK (2010) Prevalence of osteoporosis and incidence of hip fracture in women-secular trends over 30 years. BMC Musculoskelet Disord 11:48
7. Statistics Norway; available at www.ssb. no. 2009-02-10
8. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809
9. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD001155.
10. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:3-13
11. Devold HM, Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, Sogaard AJ (2010) Prescription of anti-osteoporosis drugs during 2004-2007-a nationwide register study in Norway. Eur J Clin Pharmacol 66:299-306
12. Falch JA, Ilebekk A, Slungaard U (1985) Epidemiology of hip fractures in Norway. Acta Orthop Scand 56:12-16
13. Falch JA, Kaastad TS, Bohler G, Espeland J, Sundsvold OJ (1993) Secular increase and geographical differences in hip fracture incidence in Norway. Bone 14:643-645
14. Wholesale based drug statistics; available at www.legemiddelforbruk. no. 2010-08-10.
15. Norwegian Prescription Database; available at www.norpd. no. 2010-08-10.
16. Falch JA (1996) Meyer HE [Bone mineral density measured by dual X-ray absorptiometry. A reference material from Oslo]. Tidsskr Nor Laegeforen 116:2299-2302
17. Kanis JA, Johnell O, Oden A, Jonsson B, De LC, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27:585-590
18. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124
19. Armitage P, Berry G (1994) Statistical methods in medical research.
20. Icks A, Haastert B, Wildner M, Becker C, Meyer G (2008) Hip fracture incidence in Germany: analysis of the national hospital discharge registry 2004. Dtsch Med Wochenschr 133:125-128
21. Holt G, Smith R, Duncan K, Hutchison JD, Gregori A (2008) Gender differences in epidemiology and outcome after hip fracture: evidence from the Scottish Hip Fracture Audit. J Bone Joint Surg Br 90:480-483
22. Moayyeri A, Soltani A, Larijani B, Naghavi M, Alaeddini F, Abolhassani F (2006) Epidemiology of hip fracture in Iran: results from the Iranian multicenter study on accidental injuries. Osteoporos Int 17:1252-1257
23. El MA, Koumba BA, Jroundi I, Achemlal L, Bezza A, Tazi MA (2005) Epidemiology of hip fractures in 2002 in Rabat, Morocco. Osteoporos Int 16:597-602
24. Hagino H, Katagiri H, Okano T, Yamamoto K, Teshima R (2005) Increasing incidence of hip fracture in Tottori Prefecture, Japan: trend from 1986 to 2001. Osteoporos Int 16:1963-1968
25. Soveid M, Serati AR, Masoompoor M (2005) Incidence of hip fracture in Shiraz, Iran. Osteoporos Int 16:1412-1416
26. de Pina MF, Alves SM, Barbosa M, Barros H (2008) Hip fractures cluster in space: an epidemiological analysis in Portugal. Osteoporos Int 19:1797-1804
27. Chie WC, Yang RS, Liu JP, Tsai KS (2004) High incidence rate of hip fracture in Taiwan: estimated from a nationwide health insurance database. Osteoporos Int 15:998-1002
28. Abolhassani F, Moayyeri A, Naghavi M, Soltani A, Larijani B, Shalmani HT (2006) Incidence and characteristics of falls leading to hip fracture in Iranian population. Bone 39:408-413
29. Kannus P, Parkkari J, Niemi S, Pasanen M, Palvanen M, Jarvinen M, Vuori I (2000) Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 343:1506-1513
30. Gale CR, Martyn CN, Kellingray S, Eastell R, Cooper C (2001) Intrauterine programming of adult body composition. J Clin Endocrinol Metab 86:267-272
31. Droyvold WB, Nilsen TI, Kruger O, Holmen TL, Krokstad S, Midthjell K, Holmen J (2006) Change in height, weight and body mass index: longitudinal data from the HUNT study in Norway. Int J Obes (Lond) 30:935-939
32. Statistics Norway, NSD. National health survey 2008. 2009; NSD1327.
33. Statistics Norway, NSD. National health survey 1998. 2009; NSD0415.
34. Michaelsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG, Persson I, Ljunghall S (1998) Hormone replacement therapy and risk of hip fracture: population based case-control study. BMJ 316:1858-1863
35. Meyer HE, Lofthus CM, Sogaard AJ, Falch JA (2008) Change in the use of hormone replacement therapy and the incidence of fracture in Oslo. Osteoporos Int 5:827-830
36. Lofthus CM, Frihagen F, Meyer HE, Nordsletten L, Melhuus K, Falch JA (2008) Epidemiology of distal forearm fractures in Oslo, Norway. Osteoporos Int 19:781-786
37. Cheng SY, Levy AR, Lefaivre KA, Guy P, Kuramoto L, Sobolev B (2011) Geographic trends in incidence of hip fractures: a comprehensive literature review. Osteoporos Int 10:2575-2586
38. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB (2009) Incidence and mortality of hip fractures in the United States. JAMA 302:1573-1579
39. Lofthus CM, Cappelen I, Osnes EK, Falch JA, Kristiansen IS, Medhus AW, Nordsletten L, Meyer HE (2005) Local and national electronic databases in Norway demonstrate a varying degree of validity. J Clin Epidemiol 58:280-285